IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

Dry Eye Disease Clinical Trial

Official title:

A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects Following Corneal Collagen Crosslinking (CXL)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05136924
• Other study ID #: The CIrCles Study
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 1, 2021
• Est. completion date: June 1, 2022

Study information

• Verified date: November 2021
• Source: Vance Thompson Vision - MT
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated study to Assess the Efficacy of OC-01 (varenicline) Nasal Spray on signs and symptoms of Dry Eye Disease in subjects following Corneal Collagen Crosslinking (CXL)

Description:

Rationale for Study Design This study is a single center, prospective, randomized, controlled, double-masked, two-arm investigator-initiated study to investigate the efficacy of OC-01 on signs and symptoms of dry eye disease in subjects following corneal collagen crosslinking (CXL).

2. STUDY OBJECTIVES 2.1 Primary Objective

• Mean change in NEI VFQ-25 from baseline to Day 0, Day 7, and Day 28 (1-month postoperative CXL)

• Coneal epithelial healing rate at days 2 (48 hours), 3 (72 hours), 4 (96 hours) after creation of 9 mm corneal epithelial defect as evaluated by masked physician 2.2 Secondary Objectives

• Mean change in eye dryness score (EDS) as measured by the Visual Analogue Scale (VAS) from baseline overtime to Day 28 (1 month postoperatively CXL) as measured by masked evaluator

• Mean change in corneal fluorescein staining from baseline to Day 0 (surgical day) and Day 0 to Day 28 (1-month postoperative CXL) as evaluated by masked physician

• Mean change in tear break up time (TBUT) from baseline to Day 0 (surgical day) and day 0 to day 28 (1-month postoperative CXL)

• Incidence and severity of adverse events

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: June 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be willing and able to sign the informed consent form

• Be at least 18 to 50 years of age at the screening visit

• Have best corrected manifest refraction between 20/40 to 20/100

• Remove contact lenses 2 weeks prior to surgical procedure and continue until end of study with the exception of scleral lens wearers that have no better option for correcting visual acuity

• Have planned corneal collagen crosslinking for treatment of keratoconus or corneal ectasia

• Be literate and able to complete questionnaires independently

• Be able and willing to use the study drug and participate in all study assessments and visits Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug

• Have provided verbal and written informed consent

• If a female is of childbearing potential, they must: use an acceptable means of birth control (acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives, mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), and have a negative urine pregnancy test on Baseline/Screening Day

Exclusion Criteria:

• Have presence of corneal pathology that may interfere with CXL outcomes

• At time of screening have had temporary plugs placed in the past 1 month or currently have permanent punctal plugs in place

• Active infectious, ocular, or systemic disease

• Have a history of ocular inflammation or macular edema

• Have chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the opinion of the Investigator, may lead to clinically significant risk of increased bleeding

• Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas

• Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal obstruction as confirmed by intranasal examination performed at Visit 1.

• Be currently treated with nasal continuous positive airway pressure

• Have had blepharoplasty in either eye

• Have had a corneal transplant in either eye

• Have a history of seizures or other factors that lower the subject's seizure threshold.

• Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)

• Have a known hypersensitivity to any of the procedural agents or study drug components Have current concomitant use of a nicotinic acetylcholine receptor agonist [Nicoderm®, Nicorette®, Nicotrol NS® (nicotine), Tabex®, Desmoxan® (cytisine), and Chantix® (varenicline)] within the previous 30 days of Visit 1 and during the treatment period.

• Have active or uncontrolled, severe (at the discretion of the investigator):

• Systemic allergy

• Chronic seasonal allergies at risk of being active during the study treatment period

• Rhinitis or sinusitis requiring treatment such as antihistamines, decongestants, oral or aerosol steroids at the Screening Visit or be expected to require treatment during the treatment period of the study

• Untreated nasal infection at Visit 1

• Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject

• Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1 and during the treatment period.

• Be a female who is pregnant, nursing, or planning a pregnancy at Visit 1. Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner.

Related Conditions & MeSH terms

• Dry Eye Disease
• Dry Eye Syndromes
• Eye Diseases
• Keratoconjunctivitis Sicca

Intervention

Drug:
• OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo
OC-01 nasal spray containing varenicline for treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway VS Placebo

Other:
• Placebo (vehicle) nasal spray
Placebo (vehicle) nasal spray

Locations

Country	Name	City	State
United States	Vance Thompson Vision-MT	Bozeman	Montana

Sponsors (1)

Lead Sponsor	Collaborator
Vance Thompson Vision - MT

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NEI VFQ-25 Questionnaire	questionnaire assesses effect of visual impairment on the patient's current health-related quality of life, including questions dealing with irritation in and around the eye. The score on a scale is from 0 to 100 points. A score of 0 is the worst score and a score of 100 is the best score and means the patient has no vision problems	from baseline to Day 28 (1-month postoperative CXL)
Primary	Corneal Epithelial Healing	Corneal epithelial healing rate at days 2 (48 hours), 3 (72 hours), 4 (96 hours) after creation of 9mm epithelial defect as measured by a masked physician	Up to 96 hours after creation of 9mm epithelial defect
Secondary	Dryness Scoring	Mean change in eye dryness score (EDS) as measured by the Visual Analogue Scale (VAS) from baseline over time to Day 28 (1 month postoperatively CXL) as measured by masked evaluator	from baseline over time to Day 28 (1 month postoperatively CXL)
Secondary	Corneal Fluorescein Staining	Mean change in corneal fluorescein staining from baseline to Day 0 (surgical day) and Day 7 to Day 28 (1-month postoperative CXL) as evaluated by masked physician	from baseline to Day 0 (surgical day) and Day 7 to Day 28 (1-month postoperative CXL)
Secondary	Tear Break Up Time	Mean change in tear break up time (TBUT) from baseline to Day 0 (surgical day) and Day 7 to Day 28 (1-month postoperative CXL)	baseline to Day 0 (surgical day) and Day 7 to Day 28 (1-month postoperative CXL)
Secondary	Adverse Events	Incidence and severity of adverse events	56 days (4 weeks preop and 4 weeks postop)